name: Ultrasound-guided of prostate gland through area between scrotum and anus


name: Transperineal sextant, ultrasound-localized discrete lesion(s), biopsy of prostate


name: Biopsy, prostate, transperineal, ultrasound-guided (ie, sextant) with MRI-fusion-guidance biopsy, first targeted lesion


name: Ultrasound-guided biopsy of first-targeted tumor of prostate gland with MRI-fusion guidance through area between scrotum and anus


name: Transperineal sextant biopsy of prostate, first targeted lesion, with MRI-fusion-guidance


name: Biopsy, prostate, transrectal, MRI-ultrasound-fusion guided, targeted lesion(s) only, first targeted lesion


name: MRI-ultrasound-fusion guided biopsy of prostate gland first targeted tumor only through rectum


name: Biopsy, prostate, transperineal, MRI-ultrasound-fusion guided, targeted lesion(s) only, first targeted lesion


name: MRI-ultrasound-fusion guided biopsy of prostate gland first targeted tumor only through area between scrotum and rectum


name: Biopsy, prostate, in-bore CT- or MRI-guided (ie, sextant), with biopsy of additional targeted lesion(s), first targeted lesion


name: CT- or MRI-guided biopsy of prostate gland of targeted tumors


name: In-bore CT-guided biopsy of prostate, first targeted lesion with biopsy of additional target lesion(s)


name: MRI-guided biopsy of prostate, first targeted lesion with biopsy of additional target lesion(s)


name: Biopsy, prostate, in-bore CT- or MRI-guided targeted lesion(s) only, first targeted lesion


name: CT- or MRI-guided biopsy of prostate gland of first targeted tumor


name: In-bore CT-guided biopsy of prostate, first targeted lesion, targeted lesion(s) only


name: MRI-guided biopsy of prostate, first targeted lesion, targeted lesion(s) only


name: Biopsy, prostate, each additional, MRI-ultrasound fusion or in-bore CT- or MRI-guided targeted lesion (List separately in addition to code for primary procedure)


name: MRI-ultrasound fusion, or CT-, or MRI-guided biopsy of prostate gland, each additional targeted tumor


name: In-bore CT-guided biopsy of prostate, each additional targeted lesion


name: MRI-guided biopsy of prostate,, each additional targeted lesion


name: MRI-ultrasound fusion biopsy of prostate, each additional targeted lesion


name: Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing, includes robotic assistance, when performed; with lymph node biopsy(ies) (limited pelvic lymphadenectomy)


name: Surgical removal of prostate and surrounding lymph nodes, with biopsy of lymph nodes, using an endoscope


name: Laparoscopy with radical prostatectomy and nerve sparing, with lymph node biopsies, by retropubic approach with robotic assistance


name: Laparoscopy with radical prostatectomy and nerve sparing, with lymph node biopsy(ies), by retropubic approach


name: Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing, includes robotic assistance, when performed; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes


name: Laparoscopy with radical prostatectomy and nerve sparing, with lymph node biopsies, by retropubic approach with robotic assistance, with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes


name: Laparoscopy with radical prostatectomy and nerve sparing, with lymph node biopsy(ies), by retropubic approach, with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes


name: Ablation, irreversible electroporation, prostate, 1 or more tumors, including imaging guidance, percutaneous


name: Destruction using irreversible electrical impulses of prostate tumors


name: Percutaneous ablation with irreversible electrocorporation of prostate tumor(s) with imaging guidance


name: Occlusion of intracranial or spinal cord artery


name: Percutaneous transcatheter permanent embolization of blood vessel of central nervous system for hemostasis, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of central nervous system for occlusion of vascular malformation, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of central nervous system for tumor destruction, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of central nervous system, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of spinal cord, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of intracranial blood vessel of central nervous system for hemostasis, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of intracranial blood vessel of central nervous system for occlusion of vascular malformation, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of intracranial blood vessel of central nervous system for tumor destruction, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of intracranial blood vessel, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of central nervous system, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of spinal cord for hemostasis, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of spinal cord for occlusion of vascular malformation, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of spinal cord for tumor destruction, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of spinal cord, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of intracranial blood vessel, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of neck for hemostasis, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of neck for occlusion of vascular malformation, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of neck for tumor destruction, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of neck, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of noncentral nervous system for hemostasis, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of noncentral nervous system for occlusion of vascular malformation, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of blood vessel of noncentral nervous system for tumor destruction, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of extracranial blood vessel of head for tumor destruction, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of extracranial blood vessel of head for vascular malformation, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent embolization of extracranial blood vessel of head, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of neck for hemostasis, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of neck for tumor destruction, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of neck for vascular malformation, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of neck, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of noncentral nervous system for hemostasis, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of noncentral nervous system for tumor destruction, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of noncentral nervous system for vascular malformation, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of blood vessel of noncentral nervous system, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of extracranial blood vessel of head for hemostasis, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of extracranial blood vessel of head for tumor destruction, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of extracranial blood vessel of head for vascular malformation, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous transcatheter permanent occlusion of extracranial blood vessel of head, with all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention


name: Percutaneous Decompression of Neural Elements


name: Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (ie, CT or fluoroscopy), bilateral


name: Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (ie, CT or fluoroscopy), bilateral; one interspace, lumbar


name: Partial removal of lower spine ligament from both sides of one spine interspace with release


name: Bilateral percutaneous needle decompression of one lumbar interspace, with partial removal of the ligamentum flavum, with laminotomy for access, epidurography, and CT


name: Bilateral percutaneous needle decompression of one lumbar interspace, with partial removal of the ligamentum flavum, with laminotomy for access, epidurography, and fluoroscopy


name: Bilateral percutaneous needle decompression of one lumbar interspace, with partial removal of the ligamentum flavum, with laminotomy for access, epidurography, and imaging guidance


name: Decompression, percutaneous, with partial removal of the ligamentum flavum, including laminotomy for access, epidurography, and imaging guidance (ie, CT or fluoroscopy), bilateral; additional interspace(s), lumbar (List separately in addition to code for primary procedure)


name: Partial removal of lower spine ligament from both sides of each additional spine interspace with release


name: Bilateral percutaneous needle decompression of each additional lumbar interspace, with partial removal of the ligamentum flavum, with laminotomy for access, epidurography, and CT


name: Bilateral percutaneous needle decompression of each additional lumbar interspace, with partial removal of the ligamentum flavum, with laminotomy for access, epidurography, and fluoroscopy


name: Bilateral percutaneous needle decompression of each additional lumbar interspace, with partial removal of the ligamentum flavum, with laminotomy for access, epidurography, and imaging guidance


name: Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; with repair of annular defect by implantation of bone-anchored annular closure device, including all imaging guidance, 1 interspace, lumbar (List separately in addition to code for primary procedure)


name: Partial removal of spine bone with release of lower spinal cord nerves with implantation of a bone-anchored closure device of one spine interspace


name: Hemilaminectomy and foraminotomy of single interspace of lumbar spine with decompression of nerve root, with repair of annular defect by implantation of bone-anchored annular closure device, with imaging guidance


name: Hemilaminectomy and foraminotomy of single interspace of lumbar spine with excision of herniated intervertebral disc and decompression of nerve root, with repair of annular defect by implantation of bone-anchored annular closure device, with imaging guidance


name: Hemilaminectomy and partial facetectomy of single interspace of lumbar spine with decompression of nerve root, with repair of annular defect by implantation of bone-anchored annular closure device, with imaging guidance


name: Hemilaminectomy and partial facetectomy of single interspace of lumbar spine with excision of herniated intervertebral disc and decompression of nerve root, with repair of annular defect by implantation of bone-anchored annular closure device, with imaging guidance


name: Hemilaminectomy of single interspace of lumbar spine with decompression of nerve root, with repair of annular defect by implantation of bone-anchored annular closure device, with imaging guidance


name: Hemilaminectomy of single interspace of lumbar spine with excision of herniated intervertebral disc and decompression of nerve root, with repair of annular defect by implantation of bone-anchored annular closure device, with imaging guidance


name: Hemilaminectomy, partial facetectomy, and foraminotomy of single interspace of lumbar spine with decompression of nerve root, with repair of annular defect by implantation of bone-anchored annular closure device, with imaging guidance


name: Hemilaminectomy, partial facetectomy, and foraminotomy of single interspace of lumbar spine with excision of herniated intervertebral disc and decompression of nerve root, with repair of annular defect by implantation of bone-anchored annular closure device, with imaging guidance


name: Percutaneous electrical nerve field stimulation, cranial nerves, without implantation


name: Percutaneous electrical nerve field stimulation of cranial nerves


name: Initial open implantation of baroreflex activation therapy (BAT) modulation system, including lead placement onto the carotid sinus, lead tunnelling, connection to a pulse generator placed in a distant subcutaneous pocket (ie, total system), and intraoperative interrogation and programming


name: Initial implantation of baroflex activation therapy system


name: Initial open implantation of baroreflex activation therapy (BAT) modulation system, with lead placement onto the carotid sinus, lead tunnelling, connection to a pulse generator placed in a distant subcutaneous pocket and intraoperative interrogation and programming


name: Revision or replacement of baroreflex activation therapy (BAT) modulation system, with intraoperative interrogation and programming


name: Revision or replacement of baroreflex activation therapy (BAT) modulation system, with intraoperative interrogation and programming; lead only


name: Revision or replacement of baroflex activation therapy system lead only


name: Replacement of baroreflex activation therapy (BAT) modulation system lead only, with intraoperative interrogation and programming


name: Revision of baroreflex activation therapy (BAT) modulation system lead only, with intraoperative interrogation and programming


name: Revision or replacement of baroreflex activation therapy (BAT) modulation system, with intraoperative interrogation and programming; pulse generator only


name: Revision or replacement of baroflex activation therapy system pulse generator only


name: Replacement of baroreflex activation therapy (BAT) modulation system pulse generator only, with intraoperative interrogation and programming


name: Revision of baroreflex activation therapy (BAT) modulation system pulse generator only, with intraoperative interrogation and programming


name: Removal of baroreflex activation therapy (BAT) modulation system


name: Removal of baroreflex activation therapy (BAT) modulation system; total system, including lead and pulse generator


name: Removal of baroflex activation therapy total system


name: Removal of baroreflex activation therapy (BAT) modulation system; lead only


name: Removal of baroreflex activation therapy (BAT) modulation system; pulse generator only


name: Decompression; median nerve at the carpal tunnel, percutaneous, with intracarpal tunnel balloon dilation, including ultrasound guidance


name: Release of hand nerve at carpal tunnel with balloon dilation


name: Percutaneous decompression of median nerve at the carpal tunnel, with intracarpal tunnel balloon dilation and ultrasound guidance


name: Computed tomographic angiography (CTA), head and neck, with contrast material(s), including noncontrast images, when performed, and image postprocessing


name: CT scan of blood vessels in the head and neck with contrast


name: Computed tomographic angiography (CTA) of head and neck with contrast material and image postprocessing


name: Computed tomographic (CT) cerebral perfusion analysis with contrast material(s), including image postprocessing performed with concurrent CT or CT angiography of the same anatomy (List separately in addition to code for primary procedure)


name: CT scan of brain blood flow with contrast, with image post-processing with concurrent CT or CT scan of blood vessels of same area performed at same time


name: Computed tomographic (CT) cerebral perfusion analysis with contrast material(s), including image postprocessing performed without concurrent CT or CT angiography of the same anatomy


name: CT scan of brain blood flow with contrast


name: Quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, derived from augmentative software analysis of the data set from a coronary computed tomographic angiography, with interpretation and report by a physician or other qualified health care professional


name: Computerized analysis of CT angiography data on plaque in heart arteries with interpretation and report by a physician or other qualified healthcare professional


name: 2D photon radiation treatment delivery with imaging guidance


name: Level 1 radiation treatment delivery with imaging guidance


name: Multiple-electron fields radiation treatment delivery


name: Multiple-electron fields radiation treatment delivery with imaging guidance


name: Single-electron field radiation treatment delivery


name: Single-electron field radiation treatment delivery with imaging guidance


name: 3D photon radiation treatment delivery with imaging guidance


name: IMRT photon radiation treatment delivery


name: IMRT photon radiation treatment delivery with imaging guidance


name: Level 2 single-isocenter radiation treatment delivery with imaging guidance


name: 2D multiple isocenter radiation treatment delivery with photon therapy


name: 2D multiple isocenter radiation treatment delivery with photon therapy, with imaging guidance


name: 3D multiple isocenter radiation treatment delivery with photon therapy


name: 3D multiple isocenter radiation treatment delivery with photon therapy with imaging guidance


name: 3D single-isocenter radiation treatment delivery with active motion management


name: 3D single-isocenter radiation treatment delivery with active motion management, with imaging guidance


name: 3D single-isocenter radiation treatment delivery with mixed-electron/photon field(s)


name: 3D single-isocenter radiation treatment delivery with mixed-electron/photon field(s), with imaging guidance


name: 3D single-isocenter radiation treatment delivery with total skin electrons


name: 3D single-isocenter radiation treatment delivery with total skin electrons, with imaging guidance


name: IMRT multiple isocenter radiation treatment delivery with photon therapy


name: IMRT multiple isocenter radiation treatment delivery with photon therapy, with imaging guidance


name: IMRT single-isocenter radiation treatment delivery with active motion management


name: IMRT single-isocenter radiation treatment delivery with active motion management, with imaging guidance


name: IMRT single-isocenter radiation treatment delivery with mixed-electron/photon field(s)


name: IMRT single-isocenter radiation treatment delivery with mixed-electron/photon field(s), with imaging guidance


name: IMRT single-isocenter radiation treatment delivery with total skin electrons


name: IMRT single-isocenter radiation treatment delivery with total skin electrons, with imaging guidance


name: Level 3 multiple isocenters radiation treatment delivery with photon therapy


name: Level 3 multiple isocenters radiation treatment delivery with photon therapy, with imaging guidance


name: Level 3 single-isocenter photon therapy radiation treatment delivery with active motion management


name: Level 3 single-isocenter photon therapy radiation treatment delivery with active motion management, with imaging guidance


name: Level 3 single-isocenter photon therapy radiation treatment delivery with mixed-electron/photon fields


name: Level 3 single-isocenter photon therapy radiation treatment delivery with mixed-electron/photon fields, with imaging guidance


name: Level 3 single-isocenter photon therapy radiation treatment delivery with total skin electrons


name: Level 3 single-isocenter photon therapy radiation treatment delivery with total skin electrons, with imaging guidance


name: Surface radiation therapy; superficial or orthovoltage, treatment planning and simulation-aided field setting


name: Treatment planning and simulation-aided field setting for orthovoltage surface radiation therapy


name: Treatment planning and simulation-aided field setting for superficial surface radiation therapy


name: Surface radiation therapy; superficial, delivery, </=150 kV, per fraction (eg, electronic brachytherapy)


name: Delivery of superficial surface radiation therapy


name: Superficial surface radiation therapy delivery , 150kV per fraction


name: Superficial surface radiation therapy delivery, electronic brachytherapy


name: Surface radiation therapy; orthovoltage, delivery, >150-500 kV, per fraction


name: Delivery of orthovoltage surface radiation therapy


name: Superficial surface radiation therapy, orthovoltage delivery, >150-500kV per fraction


name: Surface radiation therapy; superficial or orthovoltage, image guidance, ultrasound for placement of radiation therapy fields for treatment of cutaneous tumors, per course of treatment (List separately in addition to code for primary procedure)


name: Ultrasound guidance for placement of radiation therapy fields for treatment of skin tumors with superficial or orthovoltage surface radiation therapy


name: Orthovoltage surface radiation therapy with image guidance, ultrasound for placement of radiation therapy fields for treatment of cutaneous , per course of treatment


name: Superficial surface radiation therapy with image guidance, ultrasound for placement of radiation therapy fields for treatment of cutaneous , per course of treatment


name: Management of stereotactic body radiation therapy for lesion(s) over 1-5 sessions


name: Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of structural and copy number variants, optical genome mapping (OGM)


name: Detection of abnormalities associated with constitutional chromosomal abnormalities by optical genome mapping


name: Oncology (central nervous system tumor), DNA methylation analysis of at least 10,000 methylation sites, utilizing DNA extracted from formalin-fixed tumor tissue, algorithm(s) reported as probability of matching a reference tumor family and class, and MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation status, if performed


name: DNA methylation analysis of at least 10,000 methylation sites using DNA, reported as probability of matching a reference tumor family and class in central nervous system tumors


name: Central nervous system tumor DNA methylation analysis of at least 10,000 methylation sites, utilizing DNA extracted from formalin-fixed tumor tissue, algorithm(s) reported as probability of matching a reference tumor family and class


name: Central nervous system tumor DNA methylation analysis of at least 10,000 methylation sites, utilizing DNA extracted from formalin-fixed tumor tissue, algorithm(s) reported as probability of matching a reference tumor family and class, with MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation status


name: Susceptibility studies, antimicrobial agent; carbapenemase enzyme detection (eg, Klebsiella pneumoniae carbapenemase [KPC], New Delhi metallo-beta-lactamase [NDM], Verona integron-encoded metallo-beta-lactamase [VIM]), multiplex immunoassay, qualitative, per isolate


name: Susceptibility studies by multiplex immunoassay to detect antibiotic enzyme


name: Antimicrobial agent susceptibility study New Delhi metallo-beta-lactamase (NDM] using qualitative multiplex immunoassay for detection , per isolate


name: Antimicrobial agent susceptibility study using qualitative multiplex immunoassay for Klebsiella pneumoniae carbapenemase (KPC) detection, per isolate


name: Antimicrobial agent susceptibility study using qualitative multiplex immunoassay for Verona integron-encoded metallo-beta-lactamase (VIM) detection , per isolate


name: Antimicrobial agent susceptibility study using qualitative multiplex immunoassay for carbapenemase enzyme detection , per isolate


name: Susceptibility studies, antimicrobial agent; carbapenem resistance genes (eg, blaKPC, blaNDM, blaVIM, blaOXA-48, blaIMP), amplified probe technique, per isolate


name: Susceptibility studies by amplified probe technique to detect antibiotic resistance genes


name: Antimicrobial susceptibility study using amplified probe technique for bblaOXA-48, per isolate


name: Antimicrobial susceptibility study using amplified probe technique for blaIMPr, per isolate


name: Antimicrobial susceptibility study using amplified probe technique for blaKPC, per isolate


name: Antimicrobial susceptibility study using amplified probe technique for blaNDM, per isolate


name: Antimicrobial susceptibility study using amplified probe technique for blaVIM, per isolate


name: Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis and Neisseria gonorrhoeae, multiplex amplified probe technique


name: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by RNA multiplex amplified probe technique


name: Infectious agent detection by nucleic acid (DNA or RNA); joint space pathogens and drug resistance genes, multiplex amplified probe technique, 26 or more targets


name: Detection test for joint space pathogens and drug resistance genes


name: Detection of joint space pathogens and drug resistance genes of 26 or more targets by DNA multiplex amplified probe technique


name: Detection of joint space pathogens and drug resistance genes of 26 or more targets by RNA multiplex amplified probe technique


name: Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and influenza virus types A and B


name: Detection test for severe acute respiratory syndrome coronavirus 2 and influenza virus types A and B


name: Test for markers of rheumatoid arthritis


name: DNA next generation sequencing of 22 genes in solid tumor cancers


name: Immunoassay analysis for sFlt-1/PlGF ratio in plasma specimen, reported as a value in preeclampsia


name: Immunoassay analysis for sFlt-1/PlGF ratio in serum specimen, reported as a value in preeclampsia


name: Testing for 11 cancer drugs to predict response to each drug


name: Spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) fallopian response prediction of each drug in cancer


name: Spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian response prediction of each drug in cancer


name: Spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) peritoneal response prediction of each drug in cancer


name: Urine test for chemokines to monitor for potential kidney transplant rejection


name: Amplified probe technique testing for Herpes simplex virus types 1 and 2 and Varicella zoster virus


name: Amplified probe technique testing for infectious agents in lower respiratory tract infections


name: Test for variants to determine risk for developing blood clots


name: DNA next generation sequencing of 77 genes in pan-solid tumor cancers


name: DNA next-generation sequencing of 673 infectious disease organisms


name: Rapid whole genome and mitochondrial DNA sequencing for rare diseases


name: Rapid whole genome and mitochondrial DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in buccal specimen, results reported as positive or negative in constitutional disease/hereditary disorders


name: Rapid whole genome and mitochondrial DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in buffy coat specimen, results reported as positive or negative in constitutional disease/hereditary disorders


name: Rapid whole genome and mitochondrial DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in peripheral blood specimen, results reported as positive or negative in constitutional disease/hereditary disorders


name: Rapid whole genome and mitochondrial DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in saliva specimen, results reported as positive or negative in constitutional disease/hereditary disorders


name: Rapid whole genome and mitochondrial DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in tissue specimen, results reported as positive or negative in constitutional disease/hereditary disorders


name: Genotyping of 16 genes reported as metabolizer status and transporter function for drug metabolism


name: MicroRNA, single-nucleotide polymorphisms (SNPs) analysis of 32 variants reported as a risk score for prostate cancer


name: Testing for perfluoroalkyl substances (PFAS)


name: Quantitative analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma for perfluoroalkyl substances (PFAS)


name: Quantitative analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma for perfluorooctane sulfonic acid


name: Quantitative analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in plasma for perfluorooctanoic acid


name: Quantitative analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in serum for perfluoroalkyl substances (PFAS)


name: Quantitative analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in serum for perfluorooctane sulfonic acid


name: Quantitative analysis by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in serum for perfluorooctanoic acid


name: Red blood cell antigen (fetal RhD) testing in pregnant individuals known to be RhD negative, reported as fetal RhD status


name: DNA next-generation sequencing of more than 2500 differentiated methylated regions (DMRs), reported as positive or negative in colorectal cancer


name: DNA next generation sequencing of 600 genes, reported as actionable variant in solid tumor cancers


name: DNA next-generation sequencing of 152 genes reported as actionable variant in solid tumor cancers


name: DNA next-generation sequencing reported as a percentage of donor-derived cell-free DNA to determine probability of transplant rejection


name: Testing for 5 HAD-bound apolipoproteins reported as prediction of coronary artery disease (pCAD) score


name: Quantitative LC-MS/MS measurement of 5 distinct HDL-bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4) in serum, algorithm reported as prediction of coronary artery disease (pCAD) score


name: Nuclear magnetic resonance (NMR) spectroscopy measurement of 84 urinary metabolites reported as probability score for allograft injury status in renal transplant


name: DNA next-generation sequencing of 517 genes in solid tumor cancers


name: Testing of 48 variants reported as risk for transplant rejection


name: Digital PCR analysis in cell-free DNA in plasma, specimen, donor-derived cell-free DNA, percentage reported as risk for rejection in transplant monitoring


name: Testing for acetylcholine receptor (AChR) antibodies, reported as positive or negative


name: Testing for low-density lipoprotein receptor-related protein 4 (LRP4) antibodies, reported as positive or negative


name: Testing for neurofilament light chain (NfL)


name: Testing for glial fibrillary acidic protein (GFAP)


name: DNA testing for biomarkers reported as probability index for bladder cancer and/or upper tract urothelial carcinoma (UTUC)


name: Testing for prostate-specific antigen, reported as a risk score for the presence of high-grade prostate cancer


name: Enzyme-linked immunosorbent assays (ELISA) for total prostate-specific antigen (PSA) and free PSA in plasma specimen, combined with age, previous negative prostate biopsy status, digital rectal examination findings, prostate volume, and image and data reporting of the prostate, algorithm reported as a risk score for the presence of high-grade prostate cancer


name: Reproductive medicine (preimplantation genetic assessment), analysis for known genetic disorders from trophectoderm biopsy, linkage analysis of disease-causing locus, and when possible, targeted mutation analysis for known familial variant, reported as low-risk or high-risk for familial genetic disorder


name: Testing for genetic disorders from outer layer of embryo cells, reported as low-risk or high-risk for familial genetic disorder in preimplantation genetic assessment


name: Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophectoderm for structural rearrangements, aneuploidy, and a mitochondrial DNA score, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, or mosaic, per embryo tested


name: Analysis of 24 chromosomes using DNA genomic sequence analysis of outer layer of embryo cells, results reported as normal/balanced or balanced per embryo tested in preimplantation genetic assessment


name: Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from trophectoderm biopsy for aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal (euploidy), monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested


name: Analysis of 24 chromosomes using DNA genomic sequence analysis of outer layer of embryo cells, results reported as normal, monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, per embryo testing in preimplantation assessment


name: Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using DNA genomic sequence analysis from embryonic trophectoderm for structural rearrangements, aneuploidy, ploidy, a mitochondrial DNA score, and embryo quality control, results reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, with quality control results reported as contamination detected or inconsistent cohort when applicable, per embryo tested


name: Analysis of 24 chromosomes using DNA genomic sequence analysis of outer layer of embryo cells, results reported as reported as normal/balanced (euploidy/balanced), unbalanced structural rearrangement, monosomy, trisomy, segmental aneuploidy, triploid, haploid, or mosaic, per embryo testing in preimplantation assessment


name: Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected


name: Testing of pathogen-specific DNA and RNA by real-time PCR for 12 targets from nasal or throat swab, reported as detected or not detected in bacterial or viral respiratory tract infection


name: Pathogen-specific DNA and RNA by real-time PCR, of 12 targets in nasopharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected in bacterial respiratory tract infection


name: Pathogen-specific DNA and RNA by real-time PCR, of 12 targets in nasopharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected in viral respiratory tract infection


name: Pathogen-specific DNA and RNA by real-time PCR, of 12 targets in oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected in bacterial respiratory tract infection


name: Pathogen-specific DNA and RNA by real-time PCR, of 12 targets in oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected in viral respiratory tract infection


name: Infectious disease (bacterial vaginosis and vaginitis), real-time amplification of DNA markers for Atopobium vaginae, Gardnerella vaginalis, Megasphaera types 1 and 2, bacterial vaginosis associated bacteria-2 and -3 (BVAB-2, BVAB-3), Mobiluncus species, Trichomonas vaginalis, Neisseria gonorrhoeae, Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei), Herpes simplex viruses 1 and 2, vaginal fluid, reported as detected or not detected for each organism


name: Real-time amplification testing for bacterial DNA markers in vaginal fluid reported as detected or not detected for each organism in bacterial vaginosis and vaginitis


name: Oncology (colorectal), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted colorectal cancer protein marker (BF7 antigen), using serum, result reported as indicative of response/no response to therapy or disease progression/regression


name: Quantitative enzyme-linked immunosorbent assay (ELISA) for secreted colorectal cancer protein marker in serum, reported as response/no response to therapy or disease progression/regression


name: Oncology (breast), quantitative enzyme-linked immunosorbent assay (ELISA) for secreted breast cancer protein marker (BF9 antigen), serum, result reported as indicative of response/no response to therapy or disease progression/regression


name: Quantitative enzyme-linked immunosorbent assay (ELISA) for secreted breast cancer protein marker in serum, result reported as indicative of response/no response to therapy or disease progression/regression


name: Oncology (minimal residual disease [MRD]), genomic sequence analysis, cell-free DNA, whole blood and tumor tissue, baseline assessment for design and construction of a personalized variant panel to evaluate current MRD and for comparison to subsequent MRD assessments


name: Oncology (minimal residual disease [MRD]), genomic sequence analysis, cell-free DNA, whole blood, subsequent assessment with comparison to initial assessment to evaluate for MRD


name: Genomic sequence analysis of cell-free DNA, in whole blood specimen, subsequent assessment with comparison to initial assessment to evaluate for minimal residual disease


name: Oncology (solid tumor), targeted genomic sequence analysis, 33 genes, detection of single-nucleotide variants (SNVs), insertions and deletions, copy-number amplifications, and translocations in human genomic circulating cell-free DNA, plasma, reported as presence of actionable variants


name: Targeted genomic sequence analysis of 33 genes, detection of single-nucleotide variants (SNVs) in plasma, reported as presence of actionable variants in solid tumor cancer


name: Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative


name: Pathogen-specific nucleic acid DNA or RNA testing for 11 viral targets and 4 bacterial targets in upper respiratory specimen for each pathogen, reported as positive or negative in bacterial and/or viral respiratory tract infection


name: Qualitative DNA RT-PCR for pathogen-specific nucleic acid of 11 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in bacterial and viral respiratory tract infection


name: Qualitative DNA RT-PCR for pathogen-specific nucleic acid of 11 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in bacterial respiratory tract infection


name: Qualitative DNA RT-PCR for pathogen-specific nucleic acid of 11 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in viral respiratory tract infection


name: Qualitative RNA RT-PCR for pathogen-specific nucleic acid of 11 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in bacterial and viral respiratory tract infection


name: Qualitative RNA RT-PCR for pathogen-specific nucleic acid of 11 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in bacterial respiratory tract infection


name: Qualitative RNA RT-PCR for pathogen-specific nucleic acid of 11 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in viral respiratory tract infection


name: Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative


name: Pathogen-specific nucleic acid DNA or RNA testing for 10 viral targets and 4 bacterial targets in upper respiratory specimen, each pathogen reported as positive or negative in bacterial and/or respiratory tract infection


name: Qualitative DNA RT-PCR for pathogen-specific nucleic acid of 10 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in bacterial and viral respiratory tract infection


name: Qualitative DNA RT-PCR for pathogen-specific nucleic acid of 10 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in bacterial respiratory tract infection


name: Qualitative DNA RT-PCR for pathogen-specific nucleic acid of 10 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in viral respiratory tract infection


name: Qualitative RNA RT-PCR for pathogen-specific nucleic acid of 10 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in bacterial and viral respiratory tract infection


name: Qualitative RNA RT-PCR for pathogen-specific nucleic acid of 10 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in bacterial respiratory tract infection


name: Qualitative RNA RT-PCR for pathogen-specific nucleic acid of 10 viral targets and 4 bacterial targets, in upper respiratory specimen, each pathogen reported as positive or negative in viral respiratory tract infection


name: Oncology (hepatocellular carcinoma), next-generation sequencing methylation pattern assay to detect 6,626 epigenetic alterations, cell-free DNA, plasma, algorithm reported as cancer signal detected or not detected


name: Next-generation sequencing methylation pattern assay to detect 6626 epigenetic alterations in cell-free DNA plasma, algorithm reported as cancer signal detected or not detected in liver cancer


name: Oncology (lung), qPCR-based analysis of 13 differentially methylated regions (CCDC181, HOXA7, LRRC8A, MARCHF11, MIR129-2, NCOR2, PANTR1, PRKCB, SLC9A3, TBR1_2, TRAP1, VWC2, ZNF781), pleural fluid, algorithm reported as a qualitative result


name: qPCR-based analysis of 13 differentially methylated regions in pleural fluid, algorithm reported as a qualitative result in lung cancer


name: Rare diseases (constitutional/heritable disorders), whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variants


name: Whole-genome sequence analysis n blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variants in constitutional/heritable disorder


name: Whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions in amniocentesis sample, identification and categorization of genetic variants in constitutional/heritable disorders


name: Whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions in blood sample, identification and categorization of genetic variants in constitutional/heritable disorders


name: Whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions in chorionic villus tissue sample, identification and categorization of genetic variants in constitutional/heritable disorders


name: Whole-genome sequence analysis combination of short and long reads, for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy-number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat genes, methylation status of selected regions in saliva sample, identification and categorization of genetic variants in constitutional/heritable disorders


name: Neurology (dementia), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio), tau-protein phosphorylated at residue (eg, pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology


name: Testing for proteins by ultra high-sensitivity molecule array detection in plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology


name: Oncology (solid tumor), next-generation sequencing analysis of tumor methylation markers (>20,000 differentially methylated regions) present in cell-free circulating tumor DNA (ctDNA), whole blood, algorithm reported as presence or absence of ctDNA with tumor fraction, if appropriate


name: Next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA (ctDNA) in whole blood, algorithm reported as presence or absence of ctDNA in solid tumor cancer


name: Next-generation sequencing analysis of tumor methylation markers (>20,000 differentially methylated regions) present in cell-free circulating tumor DNA (ctDNA) in whole blood specimen, algorithm reported as presence or absence of ctDNA with tumor fraction, if appropriate


name: Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or non-elevated based on threshold comparison


name: Testing for proteins in whole blood or plasma, individual components reported with overall result of elevated or non-elevated based on threshold comparison in traumatic brain injury


name: Immunoassay analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in plasma specimen, individual components reported with the overall result of elevated or non-elevated based on threshold comparison in traumatic brain injury


name: Immunoassay analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in whole blood specimen, individual components reported with the overall result of elevated or non-elevated based on threshold comparison in traumatic brain injury


name: Oncology (solid tumor), DNA (80 genes) and RNA (10 genes), by next-generation sequencing, plasma, including single-nucleotide variants, insertions/deletions, copy-number alterations, microsatellite instability, and fusions, reported as clinically actionable variants


name: Next-generation sequencing of DNA in 80 genes and RNA in 10 genes in plasma, reported as clinically actionable variants in solid tumor cancer


name: Oncology (prostate), high-throughput telomere length quantification by FISH, whole blood, diagnostic algorithm reported as risk of prostate cancer


name: Oncology (pancreas), 3 biomarkers (glucose, carcinoembryonic antigen, and gastricsin), pancreatic cyst lesion fluid, algorithm reported as categorical mucinous or non-mucinous


name: Testing for 3 biomarkers in pancreatic cyst lesion fluid, algorithm reported as categorical mucinous or non-mucinous in pancreatic cancer


name: Mycobacterium tuberculosis, culture filtrate protein-10-kDa (CFP-10), serum or plasma, liquid chromatography mass spectrometry (LC-MS)


name: Culture filtrate protein-10-kDa testing in serum or plasma for tuberculosis


name: Liquid chromatography mass spectrometry (LC-MS) analysis for Mycobacterium tuberculosis, culture filtrate protein-10-kDa (CFP-10) in plasma specimen


name: Liquid chromatography mass spectrometry (LC-MS) analysis for Mycobacterium tuberculosis, culture filtrate protein-10-kDa (CFP-10) in serum specimen


name: Transplantation medicine (liver allograft rejection), miRNA gene expression profiling by RT-PCR of 4 genes (miR-122, miR-885, miR-23a housekeeping, spike-in control), serum, algorithm reported as risk of liver allograft rejection


name: miRNA gene expression profiling by RT-PCR of 4 genes in serum reported as risk of liver transplant rejection


name: Transplantation medicine (liver allograft rejection), quantitative donor-derived cell-free DNA (cfDNA) by whole genome next-generation sequencing, plasma and mRNA gene expression profiling by multiplex real-time PCR of 56 genes, whole blood, combined algorithm reported as a rejection risk score


name: Whole genome next-generation sequencing in plasma and mRNA gene expression profiling by multiplex real-time PCR of 56 genes in whole blood, results combined and reported as a rejection risk score in liver transplant


name: Quantitative donor-derived cell-free DNA (cfDNA) by whole genome next-generation sequencing in plasma specimen and mRNA gene expression profiling by multiplex real-time PCR of 56 gene in whole blood specimen, combined algorithm reported as a rejection risk score in liver transplant


name: Oncology (ovarian), serum, analysis of 39 glycoproteins by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in multiple reaction monitoring mode, reported as likelihood of malignancy


name: Analysis of proteins reported as likelihood of malignancy in ovarian cancer


name: Oncology (cutaneous melanoma), RNA, gene expression profiling by real-time qPCR of 10 genes (8 content and 2 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reports a binary result, either low-risk or high-risk for sentinel lymph node metastasis and recurrence


name: RNA gene expression profiling of 10 genes results reported as either low-risk or high-risk for sentinel lymph node spread and recurrence in skin cancer


name: Nephrology (diabetic chronic kidney disease), enzyme-linked immunosorbent assay (ELISA) of apolipoprotein A4 (APOA4), CD5 antigen-like (CD5L) combined with estimated glomerular filtration rate (GFR), age, plasma, algorithm reported as a risk score for kidney function decline


name: Test for proteins in plasma combined with estimated glomerular filtration rate and age, results reported as a risk score for kidney function decline in diabetic chronic kidney disease


name: Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG


name: Transplantation medicine, antibody to non-human leukocyte antigens (non-HLA), blood specimen, flow cytometry, single-antigen bead technology, 39 targets, individual positive antibodies reported


name: Antibody test in blood, results reported as positive for antibodies tested in transplant


name: Rare diseases (constitutional disease/hereditary disorders), rapid whole genome DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported


name: Rapid whole genome sequence analysis of blood, saliva, tissue sample for detection of abnormalities associated with constitutional/heritable diseases


name: Rapid whole genome DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in blood specimen, variants reported in constitutional disease/hereditary disorders


name: Rapid whole genome DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in saliva specimen, variants reported in constitutional disease/hereditary disorders


name: Rapid whole genome DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in tissue specimen, variants reported in constitutional disease/hereditary disorders


name: Rare diseases (constitutional disease/hereditary disorders), rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported with proband results (List separately in addition to code for primary procedure)


name: Rapid whole genome comparator sequencing of blood, saliva, tissue sample for detection of abnormalities associated with constitutional/heritable diseases


name: Rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in blood specimen, variants reported with proband results in constitutional disease/hereditary disorders


name: Rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in saliva specimen, variants reported with proband results in constitutional disease/hereditary disorders


name: Rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations in tissue specimen, variants reported with proband results in constitutional disease/hereditary disorders


name: Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative (0584U)


name: Testing for protein to detect prion disease


name: Targeted genomic sequence analysis panel, solid organ neoplasm, circulating cell-free DNA (cfDNA) analysis from plasma of 521 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, and microsatellite instability, report shows identified mutations, including variants with clinical actionability


name: Targeted genomic testing for solid organ cancer


name: Oncology, mRNA, gene expression profiling of 216 genes (204 targeted and 12 housekeeping genes), RNA expression analysis, formalin-fixed paraffin-embedded (FFPE) tissue, quantitative, reported as log2 ratio per gene


name: mRNA gene expression profiling of 216 genes in cancer


name: Therapeutic drug monitoring, 60-150 drugs and metabolites, urine, saliva, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score predicted for adverse drug effects


name: Testing for drug metabolites in urine and saliva reported as a risk score for predicting adverse drug effects


name: Quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis in saliva specimen for 60-150 drugs and metabolites, specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score predicted for adverse drug effects, in therapeutic drug monitoring


name: Quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis in urine specimen for 60-150 drugs and metabolites, specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score predicted for adverse drug effects, in therapeutic drug monitoring


name: Infectious disease (bacterial or viral), 32 genes (29 informative and 3 housekeeping), immune response mRNA, gene expression profiling by split-well multiplex reverse transcription loop-mediated isothermal amplification (RT-LAMP), whole blood, reported as continuous risk scores for likelihood of bacterial and viral infection and likelihood of severe illness within the next 7 days


name: mRNA gene expression profiling of 32 genes in whole blood, reported as risk scores for likelihood of bacterial and viral infection and likelihood of severe illness within the next 7 days


name: Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 24 PFAS compounds by high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative


name: Testing of plasma or serum for 24 perfluoroalkyl substances (PFAS) compounds


name: Quantitative high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis for 24 PFAS compounds in plasma specimen


name: Quantitative high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis for 24 PFAS compounds in serum specimen


name: Infectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism


name: Measurement of DNA of bacteria and fungi in urine


name: Oncology (prostate cancer), biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), plasma, serum, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer


name: Analysis of proteins in plasma reported as a probability score for prostate cancer


name: Biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), in plasma specimen, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer


name: Biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), in serum specimen, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer


name: Oncology (hematolymphoid neoplasms), DNA, targeted genomic sequence of 417 genes, interrogation for gene fusions, translocations, rearrangements, utilizing formalin-fixed paraffin-embedded (FFPE) tumor tissue, results report clinically significant variant(s)


name: Targeted genomic testing for blood/lymph tumors


name: Infectious disease (genitourinary pathogens), DNA, 46 targets (28 pathogens, 18 resistance genes), RT-PCR amplified probe technique, urine, each analyte reported as detected or not detected


name: Measurement of DNA of pathogens in urine, results reported as detected or not detected


name: Infectious disease (sepsis), semiquantitative measurement of pancreatic stone protein concentration, whole blood, reported as risk of sepsis


name: Measurement of protein in blood, reported as risk of blood infection


name: Infectious disease (tropical fever pathogens), vector-borne and zoonotic pathogens, including 2 viruses (Chikungunya virus and Dengue virus serotypes 1, 2, 3, and 4), 1 bacterium (Leptospira species), and 1 parasite with species differentiation (Plasmodium species, Plasmodium falciparum, and Plasmodium vivax/ovale), real-time RT-PCR, whole blood, each pathogen reported as detected or not detected


name: Measurement of tropical fever pathogens in blood, results reported as detected or not detected


name: Neurology (Alzheimer disease), plasma, 3 distinct isoform-specific peptides (APOE2, APOE3, and APOE4) by liquid chromatography with tandem mass spectrometry (LC-MS/MS), reported as an APOE prototype


name: Measurement of peptides in plasma in Alzheimer disease reported as an apolipoprotein prototype


name: Oncology (breast), RNA expression profiling of 329 genes by targeted next-generation sequencing and 20 proteins by multiplex immunofluorescence, formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic analyses to determine tumor-recurrence risk score


name: RNA gene expression profiling of 329 genes and testing of 20 proteins to determine tumor recurrence score in breast cancer


name: Gastroenterology (irritable bowel syndrome), IgG antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report as elevated (positive) or normal (negative) antibody levels


name: Testing for IgG antibodies to 18 food items in blood or serum, results reported as elevated or normal in irritable bowel syndrome


name: Microarray-based immunoassay for IgG antibodies to 18 food items in serum specimen, report as elevated (positive) or normal (negative) antibody levels in irritable bowel syndrome


name: Microarray-based immunoassay for IgG antibodies to 18 food items in whole blood specimen, report as elevated (positive) or normal (negative) antibody levels in irritable bowel syndrome


name: Oncology (pancreatic cancer), multiplex immunoassay of ICAM1, TIMP1, CTSD, THBS1, and CA 19-9, serum, diagnostic algorithm reported as positive or negative


name: Testing for biomarkers for pancreatic cancer


name: Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use


name: Immunization administration by intramuscular injection, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine


name: Administration of severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine by intramuscular injection, first component of each vaccine administered


name: Immunization administration by intramuscular injection, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine; each additional component administered (List separately in addition to code for primary procedure)


name: Immunization counseling by physician or other qualified health care professional when immunization(s) is not administered by provider on the same date of service


name: Immunization counseling by physician or other qualified health care professional when immunization(s) is not administered by provider on the same date of service; 3 minutes up to 10 minutes


name: Immunization counseling by physician or other qualified health care professional when immunization(s) is not administered by provider on the same date of service; greater than 10 minutes up to 20 minutes


name: Immunization counseling by physician or other qualified health care professional when immunization(s) is not administered by provider on the same date of service, more than 10 minutes up to 20 minutes


name: Immunization counseling by physician or other qualified health care professional when immunization(s) is not administered by provider on the same date of service; greater than 20 minutes


name: Immunization counseling by physician or other qualified health care professional when immunization(s) is not administered by provider on the same date of service, more than 20 minutes


name: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use


name: Influenza virus vaccine (IIV), H5, pandemic formulation, split virus, adjuvanted, for intramuscular use


name: Influenza vaccine, H5, pandemic formulation


name: Influenza virus vaccine, H5N1, derived from cell cultures, adjuvanted, for intramuscular use


name: Influenza virus vaccine, trivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 31.7 mcg/0.32 mL dosage, for intramuscular use


name: Influenza virus vaccine, quadrivalent, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 40 mcg/0.4 mL dosage, for intramuscular use


name: Rectal sensation, tone, and compliance study (eg, barostat)


name: Anorectal manometry, with rectal sensation and rectal balloon expulsion test, when performed


name: Rod and cone breakpoint examination with interpretation and report


name: Rod and cone sensitivities examination with interpretation and report


name: Screening dark adaptation measurement (eg, rod recovery intercept time), with interpretation and report


name: Screening evaluation of eye adaptation to light and dark with interpretation and report


name: Rod recovery intercept time with interpretation and report


name: Evaluation for hearing aid candidacy, unilateral or bilateral, including review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, counseling on treatment options with report, and, when performed, assessment of cognitive and communication status


name: Evaluation for hearing aid candidacy, unilateral or bilateral, including review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, counseling on treatment options with report, and, when performed, assessment of cognitive and communication status; first 30 minutes


name: Evaluation for hearing aids in one or both ears, first 30 minutes


name: Evaluation for hearing aid candidacy, bilateral, with review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, counseling on treatment options with report, first 30 minutes


name: Evaluation for hearing aid candidacy, bilateral, with review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, with assessment of cognitive and communication status, counseling on treatment options with report, first 30 minutes


name: Evaluation for hearing aid candidacy, unilateral, with review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, counseling on treatment options with report, first 30 minutes


name: Evaluation for hearing aid candidacy, unilateral, with review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, with assessment of cognitive and communication status, counseling on treatment options with report, first 30 minutes


name: Evaluation for hearing aid candidacy, unilateral or bilateral, including review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, counseling on treatment options with report, and, when performed, assessment of cognitive and communication status; each additional 15 minutes (List separately in addition to code for primary procedure)


name: Evaluation for hearing aids in one or both ears, each additional 15 minutes


name: Evaluation for hearing aid candidacy, bilateral, with review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, counseling on treatment options with report, each additional 15 minutes


name: Evaluation for hearing aid candidacy, bilateral, with review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, with assessment of cognitive and communication status, counseling on treatment options with report, each additional 15 minutes


name: Evaluation for hearing aid candidacy, unilateral, with review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, counseling on treatment options with report, each additional 15 minutes


name: Evaluation for hearing aid candidacy, unilateral, with review and integration of audiologic function tests, assessment, and interpretation of hearing needs (eg, speech-in-noise, suprathreshold hearing measures), discussion of candidacy results, with assessment of cognitive and communication status, counseling on treatment options with report, each additional 15 minutes


name: Hearing aid selection services, unilateral or bilateral, including review of audiologic function tests and hearing aid candidacy evaluation, assessment of visual and dexterity limitations, and psychosocial factors, establishment of device type, output requirements, signal processing strategies and additional features, discussion of device recommendations with report


name: Hearing aid selection services, unilateral or bilateral, including review of audiologic function tests and hearing aid candidacy evaluation, assessment of visual and dexterity limitations, and psychosocial factors, establishment of device type, output requirements, signal processing strategies and additional features, discussion of device recommendations with report; first 30 minutes


name: Hearing aid selection services for one or both ears, first 30 minutes


name: Hearing aid selection services, bilateral, with review of audiologic function tests and hearing aid candidacy evaluation, assessment of visual and dexterity limitations, and psychosocial factors, establishment of device type, output requirements, signal processing strategies and additional features, discussion of device recommendations with report, first 30 minutes


name: Hearing aid selection services, unilateral, with review of audiologic function tests and hearing aid candidacy evaluation, assessment of visual and dexterity limitations, and psychosocial factors, establishment of device type, output requirements, signal processing strategies and additional features, discussion of device recommendations with report, first 30 minutes


name: Hearing aid selection services, unilateral or bilateral, including review of audiologic function tests and hearing aid candidacy evaluation, assessment of visual and dexterity limitations, and psychosocial factors, establishment of device type, output requirements, signal processing strategies and additional features, discussion of device recommendations with report; each additional 15 minutes (List separately in addition to code for primary procedure)


name: Hearing aid selection services for one or both ears, each additional 15 minutes


name: Hearing aid selection services, bilateral, with review of audiologic function tests and hearing aid candidacy evaluation, assessment of visual and dexterity limitations, and psychosocial factors, establishment of device type, output requirements, signal processing strategies and additional features, discussion of device recommendations with report, each additional 15 minutes


name: Hearing aid selection services, unilateral, with review of audiologic function tests and hearing aid candidacy evaluation, assessment of visual and dexterity limitations, and psychosocial factors, establishment of device type, output requirements, signal processing strategies and additional features, discussion of device recommendations with report, each additional 15 minutes


name: Hearing aid fitting services, unilateral or bilateral, including device analysis, programming, verification, counseling, orientation, and training, and, when performed, hearing assistive device, supplemental technology fitting services


name: Hearing aid fitting services, unilateral or bilateral, including device analysis, programming, verification, counseling, orientation, and training, and, when performed, hearing assistive device, supplemental technology fitting services; first 60 minutes


name: Hearing aid fitting services for one or both ears, first 60 minutes


name: Hearing aid fitting services, bilateral, including device analysis, programming, verification, counseling, orientation, and training, with hearing assistive device, supplemental technology fitting services, first 60 minutes


name: Hearing aid fitting services, bilateral, with device analysis, programming, verification, counseling, orientation, and training, first 60 minutes


name: Hearing aid fitting services, unilateral, including device analysis, programming, verification, counseling, orientation, and training, with hearing assistive device, supplemental technology fitting services, first 60 minutes


name: Hearing aid fitting services, unilateral, with device analysis, programming, verification, counseling, orientation, and training, first 60 minutes


name: Hearing aid fitting services, unilateral or bilateral, including device analysis, programming, verification, counseling, orientation, and training, and, when performed, hearing assistive device, supplemental technology fitting services; each additional 15 minutes (List separately in addition to code for primary procedure)


name: Hearing aid fitting services for one or both ears, each additional 15 minutes


name: Hearing aid fitting services, bilateral, including device analysis, programming, verification, counseling, orientation, and training, with hearing assistive device, supplemental technology fitting services, each additional 15 minutes


name: Hearing aid fitting services, bilateral, with device analysis, programming, verification, counseling, orientation, and training, each additional 15 minutes


name: Hearing aid fitting services, unilateral, including device analysis, programming, verification, counseling, orientation, and training, with hearing assistive device, supplemental technology fitting services, each additional 15 minutes


name: Hearing aid fitting services, unilateral, with device analysis, programming, verification, counseling, orientation, and training, each additional 15 minutes


name: Hearing aid post-fitting follow-up services, unilateral or bilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, and, when performed, hearing assistive device, supplemental technology fitting services


name: Hearing aid post-fitting follow-up services, unilateral or bilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, and, when performed, hearing assistive device, supplemental technology fitting services; first 30 minutes


name: Hearing aid post-fitting follow-up services for one or both ears, first 30 minutes


name: Hearing aid post-fitting follow-up services, bilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, first 30 minutes


name: Hearing aid post-fitting follow-up services, bilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, with hearing assistive device, supplemental technology fitting services, first 30 minutes


name: Hearing aid post-fitting follow-up services, unilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, first 30 minutes


name: Hearing aid post-fitting follow-up services, unilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, with hearing assistive device, supplemental technology fitting services, first 30 minutes


name: Hearing aid post-fitting follow-up services, unilateral or bilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, and, when performed, hearing assistive device, supplemental technology fitting services; each additional 15 minutes (List separately in addition to code for primary procedure)


name: Hearing aid post-fitting follow-up services for one or both ears, each additional 15 minutes


name: Hearing aid post-fitting follow-up services, bilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, each additional 15 minutes


name: Hearing aid post-fitting follow-up services, bilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, with hearing assistive device, supplemental technology fitting services, each additional 15 minutes


name: Hearing aid post-fitting follow-up services, unilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, each additional 15 minutes


name: Hearing aid post-fitting follow-up services, unilateral, including confirmation of physical fit, validation of patient benefit and performance, sound quality of device, adjustment(s) (eg, verification, programming adjustment[s], device connection[s], and device training), as indicated, with hearing assistive device, supplemental technology fitting services, each additional 15 minutes


name: Behavioral verification of amplification including aided thresholds, functional gain, speech-in-noise, when performed (List separately in addition to code for primary procedure)


name: Behavioral verification of amplification for hearing aids


name: Hearing-aid measurement, verification with probe-microphone (List separately in addition to code for primary procedure)


name: Hearing device verification, electroacoustic analysis


name: Hearing assistive device, supplemental technology fitting services (eg, personal frequency modulation [FM]/digital modulation [DM] system, remote microphone, alerting devices)


name: Hearing assistive device, alerting system device fitting services


name: Hearing assistive device, personal frequency modulation (FM)/digital modulation system fitting services


name: Hearing assistive device, remote microphone system fitting services


name: Balloon dilation of single coronary artery and/or its branch(es)


name: Percutaneous transluminal coronary angioplasty into single major coronary artery and its branch(es)


name: Removal of plaque with balloon dilation of single coronary artery and/or its branch(es)


name: Percutaneous transluminal coronary atherectomy into single major coronary artery and its branch(es)


name: Percutaneous transluminal coronary atherectomy with angioplasty into single major coronary artery and its branch(es)


name: Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed, single major coronary artery and/or its branch(es)


name: Insertion of stents for 1 lesion, with balloon dilation of coronary artery or branch, single artery and/or its branch(es)


name: Percutaneous transcatheter insertion of stent into single major coronary artery and its branch(es), with 1 lesion involving 1 or more coronary segments


name: Percutaneous transcatheter insertion of stent into single major coronary artery branch(es), with 1 lesion involving 1 or more coronary segments


name: Percutaneous transcatheter insertion of stent into single major coronary artery, with 1 lesion involving 1 or more coronary segments


name: Percutaneous transcatheter insertion of stent with coronary angioplasty into single major coronary artery and its branch(es) with 1 lesion involving 1 or more coronary segments


name: Percutaneous transcatheter insertion of stent with coronary angioplasty into single major coronary artery branch(es) with 1 lesion involving 1 or more coronary segments


name: Percutaneous transcatheter insertion of stent with coronary angioplasty into single major coronary artery with 1 lesion involving 1 or more coronary segments


name: Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed, single major coronary artery and/or its branch(es); 2 or more distinct coronary lesions with 2 or more coronary stents deployed in 2 or more coronary segments, or a bifurcation lesion requiring angioplasty and/or stenting in both the main artery and the side branch


name: Insertion of 2 stents for 2 or more lesions in 2 or more coronary segments or , with balloon dilation of coronary artery and/or its branch(es) or a bifurcation lesion requiring balloon dilation and/or stenting in the main artery and side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery and its branch(es), with 2 or more coronary stents deployed in 2 or more coronary segments


name: Percutaneous transcatheter insertion of stent into single major coronary artery and its branch(es), with bifurcation lesion requiring angioplasty and stenting in both the main artery and the side branch stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery and its branch(es), with coronary angioplasty, with 2 or more coronary stents deployed in 2 or more coronary segments


name: Percutaneous transcatheter insertion of stent into single major coronary artery and its branch(es), with coronary angioplasty, with a bifurcation lesion requiring angioplasty


name: Percutaneous transcatheter insertion of stent into single major coronary artery and its branch(es), with coronary angioplasty, with bifurcation lesion requiring angioplasty and stenting in both the main artery and the side branch stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery and its branch(es), with coronary angioplasty, with stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery and its branch(es), with or a bifurcation lesion requiring angioplasty


name: Percutaneous transcatheter insertion of stent into single major coronary artery and its branch(es), with stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery branch(es), with 2 or more coronary stents deployed in 2 or more coronary segments


name: Percutaneous transcatheter insertion of stent into single major coronary artery branch(es), with a bifurcation lesion requiring angioplasty


name: Percutaneous transcatheter insertion of stent into single major coronary artery branch(es), with bifurcation lesion requiring angioplasty and stenting in both the main artery and the side branch stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery branch(es), with coronary angioplasty, with 2 or more coronary stents deployed in 2 or more coronary segments


name: Percutaneous transcatheter insertion of stent into single major coronary artery branch(es), with coronary angioplasty, with a bifurcation lesion requiring angioplasty


name: Percutaneous transcatheter insertion of stent into single major coronary artery branch(es), with coronary angioplasty, with bifurcation lesion requiring angioplasty and stenting in both the main artery and the side branch stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery branch(es), with coronary angioplasty, with stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery branch(es), with stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery, with 2 or more coronary stents deployed in 2 or more coronary segments


name: Percutaneous transcatheter insertion of stent into single major coronary artery, with a bifurcation lesion requiring angioplasty


name: Percutaneous transcatheter insertion of stent into single major coronary artery, with bifurcation lesion requiring angioplasty and stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery, with coronary angioplasty, with 2 or more coronary stents deployed in 2 or more coronary segments


name: Percutaneous transcatheter insertion of stent into single major coronary artery, with coronary angioplasty, with bifurcation lesion requiring angioplasty and stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery, with coronary angioplasty, with stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery, with stenting in both the main artery and the side branch


name: Percutaneous transcatheter insertion of stent into single major coronary artery. with coronary angioplasty, with a bifurcation lesion requiring angioplasty


name: Removal of plaque, insertion of stent and balloon dilation of single coronary artery and/or its branch(es)


name: Percutaneous transluminal coronary atherectomy with angioplasty and insertion of stent into single major coronary artery and its branch(es)


name: Percutaneous transluminal coronary atherectomy with insertion of stent into single major coronary artery and its branch(es)


name: Removal of plaque, insertion of stent and/or balloon dilation of single coronary vessel and/or its branch(es)


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in a single major coronary artery with angioplasty


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in a single major coronary artery with angioplasty and insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in a single major coronary artery with atherectomy


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in a single major coronary artery with atherectomy and angioplasty


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in a single major coronary artery with atherectomy and insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in a single major coronary artery with atherectomy, angioplasty, and insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in a single major coronary artery with insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery and its branch(es) with angioplasty


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery and its branch(es) with angioplasty and insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery and its branch(es) with atherectomy


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery and its branch(es) with atherectomy and angioplasty


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery and its branch(es) with atherectomy and insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery and its branch(es) with atherectomy, angioplasty, and insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery and its branch(es) with insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery branch(es) with angioplasty


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery branch(es) with angioplasty and insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery branch(es) with atherectomy


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery branch(es) with atherectomy and angioplasty


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery branch(es) with atherectomy and insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery branch(es) with atherectomy, angioplasty, and insertion of stent


name: Percutaneous transluminal revascularization of a coronary artery bypass graft in single major coronary artery branch(es) with insertion of stent


name: Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel during heart attack of single coronary vessel and/or its branch(es) or a single bypass graft and/or its branches


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with angioplasty


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with angioplasty and insertion of stent


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with angioplasty and insertion of stent, with aspiration thrombectomy


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with angioplasty, with aspiration thrombectomy


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with atherectomy


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with atherectomy and angioplasty


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with atherectomy and angioplasty, with aspiration thrombectomy


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with atherectomy and insertion of stent


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with atherectomy and insertion of stent, with aspiration thrombectomy


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with atherectomy, angioplasty, and insertion of stent


name: Percutaneous transluminal revascularization of acute subtotal occlusion during acute myocardial infarction of a single coronary artery and its branch(es) with atherectomy, angioplasty, and insertion of stent, with aspiration thrombectomy